Australia, 20 October 2015 — ASX link here. Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today the closing of a AUD$ 10,018,644 common stock placement to sophisticated and institutional investors through the issue of 107,727,358 shares at a price of AUD $0. […]
DUBLIN, Ireland, Oct. 19, 2015 (GLOBE NEWSWIRE) — Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the initiation of a pilot field study for its product candidate NV-02, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) for the control of pain associated with osteoarthritis in cats. The initiation of this field study represents […]
Avita Medical announcement link here. · POSITIVE RESULTS FROM INTERIM UPDATE ON 20-PATIENT, RANDOMIZED, CONTROLLED STUDY OF RESTORATION OF PIGMENT IN HYPOPIGMENTED BURN SCARS · CONTINUED POSITIVE DATA FROM REPIGMENTATION TRIALS TO FORM BASIS FOR PIII PIVOTAL IDE SUBMISSION WITH US FDA NORTHRIDGE, Calif., and CAMBRIDGE, United Kingdom, 18 October 2013– Regenerative medicine Company Avita Medical Ltd. (ASX: AVH), (OTCQX:AVMXY) is […]
October 14, 2015: 9NEWS spoke exclusively to the first patient to undergo the new treatment that is giving hope to sufferers of back pain. Read more at http://www.9news.com.au/national/2015/10/14/19/04/aussie-innovation-gives-hope-to-back-pain-sufferers#b0dfx4DwJTTVgPDM.99
Harriet Alexander Sydney Morning Herald. Published: October 14, 2015 6:34PM Every minute of the night and day, for decades, Jaswir Grewal was in pain. The constant ache in his back forced him to leave his jobs as a mechanic and banana grower. The pain troubled his sleep, made him irritable with his wife, depressed about his […]
Northridge, CA and Cambridge, United Kingdom, 7 October 2015 Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today announced it has received CE Mark authorization to market in Europe that will allow it to define and target its autologous cell suspension technology for […]
Link here.
Northridge, CA and Cambridge, United Kingdom, 5 October 2015 Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced approval from the U.S. Food and Drug Administration (FDA) for the expansion of its Compassionate Use Investigational Device Exemption (IDE) program for ReCell®. The IDE […]
SEA: NZX and Media Release 30 September 2015. NZX link here. SeaDragon raises $10.009 million via rights offer and shortfall bookbuild, and additional placement Successful capital raising at $0.008 per share facilitates the completion of the company’s new Omega-3 fish oil refinery. New Zealand’s leading refiner and blender of high-quality fish oils SeaDragon Limited (NZX:SEA) today […]
Link here. 30 September 2015. Highlights: BARDA contract commits initial USD16.9m to support Avita’s FDA approval trial for treatment of thermal burn injuries and procure 5000-plus ReCell® devices. Contract also establishes a strategic, Avita-managed stockpile for ReCell® devices to supply nationally. A further potential to receive USD37M in contract options to support additional clinical trials and […]